Regarding the low expression of ACE2 by hepatocytes, direct liver damage requires further investigations.46 Serum GGT, as a diagnostic marker for cholangiocyte injury, has been found at elevated levels in up to 72% of severe COVID-19 patients.47 Hence, cholangiocytes are more likely to be targeted by SARS-CoV-2 and contribute to liver injury.48 This evidence concerns the gene ACE2 and COVID-19.